PLX 5568

Drug Profile

PLX 5568

Alternative Names: PLX5568; R 7376; RG7376

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Plexxikon
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Pain; Polycystic kidney disease

Most Recent Events

  • 04 Apr 2011 Plexxikon has been acquired by Daiichi Sankyo Company
  • 22 Sep 2010 Phase-I development is ongoing in healthy volunteers (for Polycystic kidney disease and Pain)
  • 09 Jan 2009 PLX 5568 licensed to Roche worldwide for the treatment of Polycystic kidney disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top